BCM
GNCA

BlueCrest Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

BlueCrest Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,241
Closed -$76K – 1678
2018
Q3 		$76K Sell
12,241
-23,467
-66% -$124K ﹤0.01% 1415
2018
Q2 		$244K Buy
+35,708
New +$267K 0.01% 1220

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlueCrest Capital Management's GNCA Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2018, closing a stake of 12,241 shares — an estimated $76K sold.

BlueCrest Capital Management first reported a position in GNCA in Q2 2018 and held it in 2 quarters. The position peaked at $244K in Q2 2018. 43 funds tracked by Wall St. Rank hold GNCA as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 12,241 Genocea Biosciences, Inc. shares in Q4 2018, an estimated $76K.
  • BlueCrest Capital Management first reported a position in Genocea Biosciences, Inc. in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Genocea Biosciences, Inc. position peaked at $244K in Q2 2018.
  • 43 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.